Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

ith gluten or gluten placebo during a 14 day period. Four doses of the oral formulation of larazotide acetate, all less than 10 mg, were given prior to each gluten challenge. Study endpoints included intestinal permeability (IP), measured as lactulose-mannitol ratio (LAMA), as well as patient signs and symptoms and outcomes, measured by the Gastrointestinal Symptoms Rating Scale (GSRS; validated in several gastrointestinal diseases) and the Psychological General Well-Being Index (PGWBI).

Clinical Findings:

* In the primary study outcome, the prevention of increase in LAMA ratio

from Day 0 to Day 14, the treatment groups showed a dose dependent

protection from increase in intestinal permeability as measured by LAMA

ratio versus placebo, however the difference was not statistically


* In the highest dose active treatment groups of 4 and 8 mg, the LAMA

ratio did not increase after gluten exposure when compared with placebo

* Post-hoc analysis of change in LAMA ratio from Day 7 to Day 21 showed

dose dependent prevention of increase in LAMA across the 4 and 8 mg

treatment groups

* Changes in PGWBI scores and anti-tTG titers were not significant over

the time course of this study

* An unexpected enrollment effect resulted in a fall in intestinal

permeability from Day 0 to Day 7 across all groups suggesting the need

for a run-in period

* Larazotide acetate conferred protection from gastrointestinal symptoms

as measured by the GSRS as well as from expected signs and symptoms of

gluten toxicity

* Follow-up studies of longer duration are currently ongoing


* There was no difference in rate of adverse events between Placebo and

Active Drug Groups (46% vs. 55%)

* No Serious Adverse Events (SAEs) were reported

* Headache was the most common AE (reported by

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... July 22, 2014  Vernalis plc (LSE: VER) and Tris ... (POC) for CCP-08, the third programme to achieve ... collaboration. Under this collaboration, POC requires the successful ... pilot comparative study against an immediate release reference ... will make a milestone payment to Tris. ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... 2014 Cloud+MD Office 2.0 ... suite of medical software and services, designed by ... that produces “Actionable Information” to help Independent Physician ... and Billing Services optimize a wide range of ... Greater Efficiency, Noticeable Cost Reductions and Better Patient ...
(Date:7/22/2014)... For the past nine years, the ... working in tandem to help thousands of cancer patients ... care, and help survivors connect to resources dealing with ... their partnership to include referrals from PAF to LIVESTRONG ... other practical, emotional, and financial issues that accompany a ...
(Date:7/22/2014)... Joining Conquer Paralysis Now as its first champion in ... Paralympic silver medalist and quadriplegic Jennifer French. , As a ... a spinal cord injury in 1998. Now, she has joined ... , “People define cure differently,” French said. “For some, it’s ... the image in our minds of what we were like ...
(Date:7/22/2014)... July 22, 2014 Altec Products, ... workflow solutions, announced today their Gold Sponsorship of ... at Mandalay Bay Hotel and Casino in Las Vegas, ... Summit draws thousands interested in taking advantage of the ... to solve business problems and educate themselves on the ...
(Date:7/22/2014)... Bramal LED announced that they will be ... Jr, airing later this year via Discovery Channel. Dates and ... about Bramal LED’s T-10 lamps, which provide over 80,000 hours ... to 70 percent. Bramal LED’s T-10 lamps can be plugged ... or on direct AC voltage, with no need for an ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2
... joint becomes inflamed. Treatment is often difficult and recovery ... the pain of this common condition. ,Now, an ... with extracorporeal shock wave therapy. During the therapy, ultrasound ... takes two to three 20-minute shock wave treatments to ...
... located at the base of the hair follicle. Hair ... In many people with hair loss, however, // the ... of abnormal follicles entering longer resting phases and producing ... University of Pennsylvania School of Medicine have isolated stem ...
... say there could be a new way to help prevent ... // increase high-density lipoprotein levels, also known as good cholesterol. ... for heart disease. They are commonly used to lower low-density ... target is a low level of good cholesterol. In fact, ...
... Toronto conducted a study to examine whether current procedures ... antibiotics // unnecessarily. Out of an estimated 6.7 million ... Doctors also researched the use of throat cultures and ... who were prompted to seek medical help for their ...
... attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent of ... increased attention problems at age 7 among kids was seen ... toddlers.The study tracked the number of hours kids watched television ... two hours of television a day. Three-year-olds watched about three ...
... warnings from the Food and Drug Administration may leave ... what they claim.// ,Some of the products ... Blocker, and Zone Fat Blocker.Many of these supplements claim ... consumers to lose weight without making any lifestyle changes. ...
Cached Medicine News:
Long handle occluder - Black...
Double Ended Occluders...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: